Editor's note

This ExpertREACT article was originally published on 28 January 2010. Financial data and market positions described reflect the state of knowledge at that date.

Novartis V&D: a $1bn windfall

Novartis AG's full year 2009 group results showed an 11% rise in net sales to $44.3bn, with growth across all divisions. For the Vaccines & Diagnostics (V&D) division - formerly Chiron, acquired for ~$5.1bn in 2006 - 2009 was a transformative year. V&D recorded full year 2009 revenues of $2,424m, a 38% increase on $1,759m in 2008. The large increase was driven by an additional $1bn in H1N1 monovalent pandemic vaccine sales following shipment of approximately 100 million doses to governments worldwide. The H1N1 boost contributed to a sharp increase in V&D operating income, which rose to $372m in 2009 from a meagre $78m in 2008 - finally making the Chiron acquisition look commercially worthwhile. V&D headcount rose 13% to 5,416 employees.

Other major H1N1 vaccine suppliers were expected to report similarly exceptional results. GSK confirmed that approximately 130 million doses had been shipped in Q4 2009 - potentially equivalent to £835m (~$1.3bn) in unaudited Q4 sales - and had also donated 60 million doses to the WHO. Sanofi Pasteur, the major seasonal influenza player, had received commitments for over 250 million H1N1 doses for 2009-2010, likely translating to $2-3bn in revenues once the exact Q4 2009 recognition was clarified at their February results release.

Novartis V&D operating income
$372m
Up from $78m in 2008; driven by $1bn in H1N1 pandemic vaccine revenues and approximately 100m doses shipped to governments worldwide

Sustainability and the post-pandemic question

VacZine Analytics questioned how long the H1N1 boost would continue. Novartis itself guided that "modest upside" remained in 2010, though production of H1N1 vaccine had largely ceased as government orders were fulfilled. The key strategic question for Novartis - and for the broader industry - was whether the pandemic infrastructure and manufacturing surge capacity built during H1N1 would translate into sustainable competitive advantage in the post-pandemic period. Meningococcal vaccines - particularly Menveo ACWY and the eagerly anticipated MenB programme - were identified as the most credible near-term replacements for the pandemic revenue stream.